Guggenheim Maintains Buy on ANI Pharmaceuticals, Raises Price Target to $121
Benzinga Newsdesk 12 hours ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Vamil Divan maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and raises the price target from $119 to $121.
Guggenheim analyst Vamil Divan maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and raises the price target from $119 to $121.